- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Snow in Vienna fails to dampen ECR attendees' enthusiasm
Freezing temperatures, snow showers, and travel delays did not deter delegates at ECR 2005. The total attendance figure rose above 14,000, although the number of professional delegates declined slightly (8422 compared with 8677 in 2004). More than 1000 professional attendees traveled from Italy for this year's congress. Also present were 823 participants from Germany, 726 from Austria, 378 from the U.K., 332 from Poland, 311 from Greece, 303 from Hungary, 274 from Spain, 267 each from Norway and Sweden, 234 from France, 216 from the Netherlands, and about 200 each from Switzerland, Russian Federation, Denmark, the U.S., Japan, and the Czech Republic.
Freezing temperatures, snow showers, and travel delays did not deter delegates at ECR 2005. The total attendance figure rose above 14,000, although the number of professional delegates declined slightly (8422 compared with 8677 in 2004). More than 1000 professional attendees traveled from Italy for this year's congress. Also present were 823 participants from Germany, 726 from Austria, 378 from the U.K., 332 from Poland, 311 from Greece, 303 from Hungary, 274 from Spain, 267 each from Norway and Sweden, 234 from France, 216 from the Netherlands, and about 200 each from Switzerland, Russian Federation, Denmark, the U.S., Japan, and the Czech Republic.
Next year's ECR will include a foundation course on musculoskeletal radiology and a categorical course on cancer staging. The host countries will be the U.K., Russia, and Singapore, and the president will be Prof. Andy Adam from Guy's, King's and St. Thomas' Medical School, University of London.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Researchers Show Higher Breast Cancer Upstaging Rate with 18F-FAPI PET/CT
September 9th 2024The imaging agent 18F-FAPI PET/CT demonstrated greater than a 45 percent higher sensitivity rate in comparison to 18F-FDG PET/CT for the detection of axillary and extraaxillary regional lymph node metastases, according to a lesion-based analysis from a recent study.
